LAMPIT

Peak

nifurtimox

NDAORALTABLETPriority Review
Approved
Aug 2020
Lifecycle
Peak
Competitive Pressure
30/100
Clinical Trials
9

Mechanism of Action

[see Microbiology ()] .

Indications (1)

Clinical Trials (5)

NCT05477953N/ANot Yet Recruiting

An Observational Pregnancy Safety Study in Women Who Were Exposed to the Drug Nifurtimox During Pregnancy to Learn About the Risk of Pregnancy Complications and About the Mother's and Baby's Health

Started Jun 2026
50 enrolled
Chagas Disease
NCT03334838Phase 1Completed

Study to Assess the Food Effect on the Pharmacokinetics of Nifurtimox Tablets in Chronic Chagas' Patients - Dietary Habits Study

Started Jun 2019
36 enrolled
Chagas' Disease
NCT03784391N/ACompleted

Study on Benefits of Therapy With Nifurtimox in Chagas Disease, a Parasitic Illness Mostly Transmitted to Humans by a Bug, Using Information From Patient Medical Records in Argentina

Started Dec 2018
3,000 enrolled
Chagas' Disease
NCT03708133Phase 1Completed

Study to Assess Bioequivalence of a New Nifurtimox Oral Tablet Formulation

Started Dec 2018
24 enrolled
Bioequivalence
NCT03350295Phase 1Completed

Study Will Evaluate the Relative Bioavailability, Safety, and Tolerability of Single Doses of Nifurtimox 30 mg Tablets Exhibiting Different in Vitro Dissolution Characteristics, and to Evaluate the Relative Bioavailability of Nifurtimox 30 mg and 120 mg

Started Jun 2018
48 enrolled
Chagas Disease